Abstract
Apoptosis is a tightly regulated physiologic process of programmed cell death that occurs in both normal and pathologic tissues. Numerous in vitro or in vivo studies have indicated that cardiomyocyte death through apoptosis and necrosis is a primary contributor to the progression of anthracycline-induced cardiomyopathy. There are now several pieces of evidence to suggest that activation of intrinsic and extrinsic apoptotic pathways contribute to anthracyclineinduced apoptosis in the heart. Novel strategies were developed to address a wide variety of cardiotoxic mechanisms and apoptotic pathways by which anthracycline influences cardiac structure and function. Anthracycline-induced apoptosis provides a very valid representation of cardiotoxicity in the heart, an argument which has implications for the most appropriate animal models of damaged heart plus diverse pharmacological effects. In this review we describe various aspects of the current understanding of apoptotic cell death triggered by anthracycline. Differences in the sensitivity to anthracycline-induced apoptosis between young and adult hearts are also discussed.
Keywords: Pediatric, cardiomyopathy, anthracycline, Apoptosis, Cytochrome C, Dexrazoxane, Intrinsic, Mitochondria, extrinsic, caspase
Current Pediatric Reviews
Title: Apoptosis in Anthracycline Cardiomyopathy
Volume: 7 Issue: 4
Author(s): Jianjian Shi, Eltyeb Abdelwahid and Lei Wei
Affiliation:
Keywords: Pediatric, cardiomyopathy, anthracycline, Apoptosis, Cytochrome C, Dexrazoxane, Intrinsic, Mitochondria, extrinsic, caspase
Abstract: Apoptosis is a tightly regulated physiologic process of programmed cell death that occurs in both normal and pathologic tissues. Numerous in vitro or in vivo studies have indicated that cardiomyocyte death through apoptosis and necrosis is a primary contributor to the progression of anthracycline-induced cardiomyopathy. There are now several pieces of evidence to suggest that activation of intrinsic and extrinsic apoptotic pathways contribute to anthracyclineinduced apoptosis in the heart. Novel strategies were developed to address a wide variety of cardiotoxic mechanisms and apoptotic pathways by which anthracycline influences cardiac structure and function. Anthracycline-induced apoptosis provides a very valid representation of cardiotoxicity in the heart, an argument which has implications for the most appropriate animal models of damaged heart plus diverse pharmacological effects. In this review we describe various aspects of the current understanding of apoptotic cell death triggered by anthracycline. Differences in the sensitivity to anthracycline-induced apoptosis between young and adult hearts are also discussed.
Export Options
About this article
Cite this article as:
Shi Jianjian, Abdelwahid Eltyeb and Wei Lei, Apoptosis in Anthracycline Cardiomyopathy, Current Pediatric Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339611796892265
DOI https://dx.doi.org/10.2174/157339611796892265 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets Aging as an Evolvability-Increasing Program Which can be Switched Off by Organism to Mobilize Additional Resources for Survival
Current Aging Science The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Angiogenetic Potential of Ad2/Hif-1α/Vp16 after Regional Application in a Preclinical Pig Model of Chronic Ischemia
Current Vascular Pharmacology Endoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Current Hypertension Reviews Connexin43 and Myocardial Ischemia-Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs
Current Drug Metabolism Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Markers of Atherosclerotic Disease: What do they Mean? Current Opinion and Future Trends
Current Pharmaceutical Design Von Willebrand Factor and Cardiovascular Disease: From a Biochemical Marker to an Attractive Therapeutic Target
Current Vascular Pharmacology Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Determination of Stimulants and Diuretics in Dietary Supplements for Weight Loss and Physical Fitness by Ion-pair Chromatography and Pulsed Amperometric Detection (PAD)
Current Analytical Chemistry NTproBNP: An Important Biomarker in Cardiac Diseases
Current Topics in Medicinal Chemistry Heme Oxygenase-1/CO as Protective Mediators in Cigarette Smoke- Induced Lung Cell Injury and Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Biotechnology Flavonoids and Chagas' Disease: The Story So Far!
Current Topics in Medicinal Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Current Signal Transduction Therapy Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design